Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2016 - 2025)
Crescent Biopharma (CBIO) reported Gains from Sales and Divestitures of $48133.0 for Q1 2025, down 17.84% year-over-year from $58581.0 in Q1 2024, and up 360.91% quarter-over-quarter from $10443.0 in Q4 2024.
Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2016 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has 10 years of Gains from Sales and Divestitures data on file, last reported at $48133.0 in Q1 2025.
- Gains from Sales and Divestitures for Q1 2025 came in at $48133.0, down 17.84% year-over-year; the trailing twelve-month figure through Mar 2025 was $48133.0 (down 17.84% YoY), and the FY2024 annual result was $10443.0, down 84.66% from the prior year.
- Gains from Sales and Divestitures advanced to $48133.0 in Q1 2025 per CBIO's latest filing, from $10443.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $189792.0 in Q3 2021 and troughed at $10443.0 in Q4 2024.
- A 5-year average of $86321.5 and a median of $68055.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2021 and 2024: Gains from Sales and Divestitures jumped 82.32% in 2021, then tumbled 84.66% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $189792.0 in 2021, then tumbled by 42.02% to $110050.0 in 2022, then sank by 38.16% to $68055.0 in 2023, then plunged by 84.66% to $10443.0 in 2024, then jumped by 360.91% to $48133.0 in 2025.
- Business Quant data shows CBIO's Gains from Sales and Divestitures at $48133.0 in Q1 2025, $10443.0 in Q4 2024, and $58581.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 48,133.00 |
| Mar 31, 2025 | 48,133.00 |
| Dec 31, 2024 | 10,443.00 |
| Dec 31, 2024 | 10,443.00 |
| Sep 30, 2024 | 58,581.00 |
| Sep 30, 2024 | 58,581.00 |
| Jun 30, 2024 | 58,581.00 |
| Jun 30, 2024 | 58,581.00 |
| Mar 31, 2024 | 58,581.00 |
| Mar 31, 2024 | 58,581.00 |
| Dec 31, 2023 | 68,055.00 |
| Dec 31, 2023 | 68,055.00 |
| Sep 30, 2023 | 68,055.00 |
| Sep 30, 2023 | 68,055.00 |
| Jun 30, 2023 | 68,055.00 |
| Jun 30, 2023 | 68,055.00 |
| Mar 31, 2023 | 68,054.00 |
| Mar 31, 2023 | 68,054.00 |
| Dec 31, 2022 | 110,050.00 |
| Dec 31, 2022 | 110,050.00 |